What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?
Open Access
- 1 September 2021
- journal article
- editorial
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 154 (3) , 405-409
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and ClarithromycinAntimicrobial Agents and Chemotherapy, 2016
- Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' PerspectivesTuberculosis and Respiratory Diseases, 2016
- Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung DiseaseChest, 2014
- In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial DiseaseAntimicrobial Agents and Chemotherapy, 2012
- Commercial DNA Probes for Mycobacteria Incorrectly Identify a Number of Less Frequently Encountered SpeciesJournal of Clinical Microbiology, 2010
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Meta-Analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without Solid Media, for Detection of MycobacteriaJournal of Clinical Microbiology, 2004
- The GlycylcyclinesDrugs, 2004
- Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria.2003